Of note, the average level of TDRD1 promoter methylation was inversely correlated with TDRD1 mRNA levels across all 93 samples (ρ = -0.57), suggesting that loss of promoter methylation substantially contributes to TDRD1 overexpression in TMPRSS2:ERG fusion-positive prostate cancer (Fig. 3b). The gene discussed is TMPRSS2; the disease is prostate cancer.